CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
CCI-779 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00483262
NCT00483262Phase 2Completed
CompareCT.gov

Phase I/II Trial of Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Dana-Farber Cancer Institute·interventional·Posted Jun 6, 2007·Updated Nov 11, 2013

In Brief

A Phase 2 clinical trial evaluating CCI-779 and Bortezomib for Multiple Myeloma. Completed, enrolled 63 participants across 3 sites.

Detailed Summary

The purpose of this research study is to determine the safety of CCI-779 (Temsirolimus) and bortezomib (Velcade), and the highest dose of this drug that can be given to people safely. We will also be looking at how the combination of the two drugs may work against multiple myeloma. CCI-779 (Temsirolimus) is a drug that appears to stop myeloma cells from growing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsWyeth is now a wholly owned subsidiary of Pfizer, Millennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 6, 2007
Enrollment StartMay 1, 2007
Primary CompletionJan 1, 2011
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 19.1 years ago

Interventions

CCI-779drug

Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles

Bortezomibdrug

Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles